Manuel Montero-Odasso1, Susan W Muir-Hunter2, Afua Oteng-Amoako3, Karen Gopaul3, Anam Islam3, Michael Borrie4, Jennie Wells4, Mark Speechley5. 1. "Gait and Brain Lab", Parkwood Hospital and Lawson Health Research Institute, London, ON, Canada Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health, University of Western Ontario, London, ON, Canada. 2. "Gait and Brain Lab", Parkwood Hospital and Lawson Health Research Institute, London, ON, Canada Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. 3. "Gait and Brain Lab", Parkwood Hospital and Lawson Health Research Institute, London, ON, Canada. 4. Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. 5. Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health, University of Western Ontario, London, ON, Canada.
Abstract
BACKGROUND:Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer's disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. OBJECTIVE: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, on gait in older adults newly diagnosed with AD. METHODS: Phase II clinical trial in 43 seniors with mild AD who receiveddonepezil. Participants had not previously received treatment with cognitive enhancers. Primary outcome variables were gait velocity (GV) and stride time variability (STV) under single and dual-task conditions measured using an electronic walkway. Secondary outcomes included attention and executive function. RESULTS: After four months of treatment, participants with mild AD improved their GV from 108.4 ± 18.6 to 113.3 ± 19.5 cm/s, p = 0.010; dual-task GV from 80.6 ± 23.0 to 85.3 ± 22.3 cm/s, p = 0.028. Changes in STV were in the expected direction although not statistically significant. Participants also showed improvements in Trail Making Tests A (p = 0.030), B (p = 0.001), and B-A (p = 0.042). CONCLUSION:Donepezil improved gait in participants with mild AD. The enhancement of dual-task gait suggests the positive changes achieved in executive function as a possible causal mechanism. This study yielded a clinically significant estimate of effect size; as well, the findings are relevant to the feasibility and ethics considerations for the design of a Phase III clinical trial.
RCT Entities:
BACKGROUND: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer's disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. OBJECTIVE: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, on gait in older adults newly diagnosed with AD. METHODS: Phase II clinical trial in 43 seniors with mild AD who received donepezil. Participants had not previously received treatment with cognitive enhancers. Primary outcome variables were gait velocity (GV) and stride time variability (STV) under single and dual-task conditions measured using an electronic walkway. Secondary outcomes included attention and executive function. RESULTS: After four months of treatment, participants with mild AD improved their GV from 108.4 ± 18.6 to 113.3 ± 19.5 cm/s, p = 0.010; dual-task GV from 80.6 ± 23.0 to 85.3 ± 22.3 cm/s, p = 0.028. Changes in STV were in the expected direction although not statistically significant. Participants also showed improvements in Trail Making Tests A (p = 0.030), B (p = 0.001), and B-A (p = 0.042). CONCLUSION:Donepezil improved gait in participants with mild AD. The enhancement of dual-task gait suggests the positive changes achieved in executive function as a possible causal mechanism. This study yielded a clinically significant estimate of effect size; as well, the findings are relevant to the feasibility and ethics considerations for the design of a Phase III clinical trial.
Authors: Kenneth A Scott; Eli Rogers; Marian E Betz; Lilian Hoffecker; Guohua Li; Carolyn DiGuiseppi Journal: J Am Geriatr Soc Date: 2017-09-05 Impact factor: 5.562
Authors: Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak Journal: Parkinsonism Relat Disord Date: 2016-07-17 Impact factor: 4.891
Authors: Sunwook Kim; Maury A Nussbaum; Paul J Laurienti; Haiying Chen; Sara A Quandt; Dana Boyd Barr; Thomas A Arcury Journal: J Occup Environ Med Date: 2018-02 Impact factor: 2.162
Authors: Vijay R Varma; Jeffrey M Hausdorff; Stephanie A Studenski; Caterina Rosano; Richard Camicioli; Neil B Alexander; Wen G Chen; Lewis A Lipsitz; Michelle C Carlson Journal: J Gerontol A Biol Sci Med Sci Date: 2016-05-06 Impact factor: 6.053
Authors: Yves J Gschwind; Stephanie A Bridenbaugh; Sarah Reinhard; Urs Granacher; Andreas U Monsch; Reto W Kressig Journal: Aging Clin Exp Res Date: 2017-02-08 Impact factor: 3.636
Authors: Manuel Montero-Odasso; Frederico Pieruccini-Faria; Robert Bartha; Sandra E Black; Elizabeth Finger; Morris Freedman; Barry Greenberg; David A Grimes; Robert A Hegele; Christopher Hudson; Peter W Kleinstiver; Anthony E Lang; Mario Masellis; Paula M McLaughlin; Douglas P Munoz; Stephen Strother; Richard H Swartz; Sean Symons; Maria Carmela Tartaglia; Lorne Zinman; Michael J Strong; William McIlroy Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472